Growth centered on the medical business under the mid-term management plan “EXCITE300”

「On 14 February 2025, we announced the Medium-Term Management Plan EXCITE300, targeting revenue of ¥15.5 billion, EBITDA of ¥2.3 billion, operating income of ¥1.6 billion, net income attributable to owners of the parent of ¥1.0 billion, and a market capitalization of ¥30.0 billion for the fiscal year ending March 2028. As segment-specific strategies to achieve these targets, the medical business will expand its medical specialties, number of clinics, delivery areas, and patient-referral channels, while the SaaS and DX businesses will strengthen their sales and customer-success structures centered on FanGrowth and Sharely.」

「To achieve the Medium-Term Management Plan EXCITE300, which targets revenue of ¥15.5 billion, EBITDA of ¥2.3 billion, operating income of ¥1.6 billion, net income attributable to owners of the parent of ¥1.0 billion, and a market capitalization of ¥30.0 billion for the fiscal year ending March 2028, the Group expects growth centered on the medical field. To present progress under the plan more clearly and more rigorously reflect the management approach of aligning organizational and disclosure segment classifications, medical services such as online medical consultations previously included in the platform business have been separated and added as a newly established reportable segment, the medical business, from the current interim consolidated accounting period.」